[Prognostic Value of SLC25A12 Expression in Patients with Acute Myeloid Leukemia Based on Integrated Analysis of Multi-dimensional Clinical Data].

Objective: To investigate the clinical and prognostic value of SLC25A12 in patients with acute myeloid leukemia (AML).

Methods: The expression levels of SLC25A12 in bone marrow or peripheral blood cells of AML patients and healthy people in two independent cohorts (n=46, n=290, respectively) were compared. Then it was assessed that the prognostic value of SLC25A12 expression in two independent AML study cohorts (n=163, n=329, respectively) by mean of integrated analysis of genomic, transcriptome, clinical and prognosis information.

Results: The expression of SLC25A12 in AML patients significantly increased as compared with that of healthy people (P=0.0001, P=0.0238, respectively). Univariate and multivariate analyze showed that high SLC25A12 expression was significantly associated with shorter event-free survival (EFS)(HR=1.605, P=0.018) and overall survival (OS)(HR=1.818, P=0.002) of patients. In favorable-risk and intermediate-risk subgroups, patients with high SLC25A12 expression showed shorter EFS and OS than patients with low SLC25A12 expression.

Conclusion: High SLC25A12 expression significantly associated with poor prognosis of AML patients, which suggests that SLC25A12 aberrant expression can be used as a potential molecular marker for prognosis evaluation of AML patients.